Objective
Patient availability is one of the key elements associated with the successful execution of rare disease drug trials, and at the
same time a major bottleneck that increases drug development time and cost. Patient recruitment is responsible for 25-30% of the total costs of a clinical trial, for adding substantially to the duration of a trial, and for the failure of 1 in 3 Phase 3 clinical
trials. Decodeon aims to transform this bottleneck into a major node in the value chain by developing and deploying structured and efficient patient registries for pharma companies and Contract Research Organisations (CROs). In doing so, Decodeon aims to overhaul this major inefficiency in clinical trial management, while tapping into an unexplored market worth €2.5 billion.
Currently, big pharma tenders clinical trials to CROs, who perform a trial for e.g. a lump sum. Decodeon will provide CROs with rare disease patients who have pre-consented with inclusion in a clinical trial, filtered based on the specific inclusion/exclusion criteria of the trial, and at the required numbers. As a consequence, CRO efficiency will increase, through lowering the time required for patient recruitment and the associated costs. Support for our novel platform is demonstrated through letters of support, annexed to this proposal.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine psychiatry sleep disorders
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- social sciences economics and business business and management business models
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3512 BT UTRECHT
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.